https://admin.akerolabs.com/login
Akero | Admin
akeroadmin
https://akerotx.com/
Akero Therapeutics | EFX for MASH | Metabolic Disease | Home
Dec 5, 2025 - Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH).
metabolic diseaseakerotherapeuticsefxmash
https://akerolabs.com/
Home - Akero
Nov 14, 2023 - The student advertising and conversion platform, powered by AI, supported by Higher Education experts.
akero
https://pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/novo-nordisk-to-expand-mash-portfolio-with-5-2-bn-akero-therapeutics-buyout/124450599
Novo Nordisk to expand MASH portfolio with $5.2 Bn Akero Therapeutics buyout, ETPharma
Novo Nordisk: The weight-loss major is pushing the acquisition to onboard a late-stage liver disease candidate, Efruxifermin, in exchange for a total cash...
https://www.benzinga.com/analyst-ratings/23/06/32755467/analyst-expectations-for-akero-therapeuticss-future
Analyst Expectations for Akero Therapeutics's Future - Benzinga
analystexpectationsakerotherapeuticsfuture
https://www.prnewswire.com/news-releases/akero-therapeutics-reports-first-quarter-2020-financial-results-301058822.html
Akero Therapeutics Reports First Quarter 2020 Financial Results
/PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines...
first quarterakerotherapeuticsreportsfinancial